84 results
Page 2 of 5
8-K
EX-3.1
13yy57owqv
11 May 23
Amendments to Articles of Incorporation or Bylaws
5:00pm
8-K
EX-99.1
dbc1oe
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
8-K
EX-1.1
ln8uyumfpr422kx
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
424B5
dtfbq3zg0lwrpo
31 Mar 23
Prospectus supplement for primary offering
5:24pm
424B5
t2x s9cgt
29 Mar 23
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
xdfp61 7sgt9h1ha
26 Oct 22
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:32pm
8-K
EX-99.1
ji5jcsdf 4t656
27 Jul 22
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
6s5p12
27 Apr 22
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:44pm
8-K
EX-99.1
rpd821w
9 Feb 22
Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-99.1
weayzffnjf38o 72k
3 Nov 21
Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
424B5
ifi1aza n7hcy
11 Aug 21
Prospectus supplement for primary offering
4:44pm
8-K
EX-99.1
wgd3zsdsbqdq5tmgwh
28 Jul 21
Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:12pm